Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | REN | P00797 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PEPD | P12955 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114955 | 1.00 | ACE (0.46) | ACERENKDM4EF2LMNA | |
| SCHEMBL3451623 | 1.00 | ACE (0.46) | ACERENKDM4EF2LMNA | |
| SCHEMBL27775712 | 1.00 | ACE (0.46) | ACERENKDM4EF2LMNA | |
| SCHEMBL1674799 | 1.00 | ACE (0.46) | ACERENKDM4EF2LMNA | |
| SCHEMBL7272757 | 0.95 | ACE (0.43) | ACERENKDM4EF2LMNA | |
| SCHEMBL11037632 | 0.95 | ACE (0.43) | ACERENKDM4EF2LMNA | |
| Sulfuric Acid SCHEMBL28295501 | 0.92 | ACE (0.40) | ACERENKDM4EF2LMNA | |
| Sulfuric Acid SCHEMBL28295504 | 0.92 | ACE (0.40) | ACERENKDM4EF2LMNA | |
| SCHEMBL30199162 | 0.91 | DPP4 (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29416313 | 0.91 | OPRM1 (0.41) | ACERENF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1323730-B1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | BIOKINE THERAPEUTICS LTD (IL) | 2010-04-21 | — | — | EP | claimed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | claimed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-0677061-B1 | POLYPEPTIDES AND ANTI-HIV AGENTS PREPARED THEREFROM | SEIKAGAKU KOGYO CO LTD (JP) | 1999-03-03 | — | — | EP | claimed |
| US-5776899-A | Polypeptide and anti-HIV agent prepared therefrom | SEIKAGAKU CORPORATION (JP) | 1998-07-07 | — | — | US | claimed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | claimed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | claimed |
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2942059-A1 | 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Biokine Therapeutics LTD. (IL) | 2015-11-11 | — | — | EP | disclosed |
| CN-1038841-C | Polypeptide and anti-hiv agent prepared therefrom | SEIKAGAKU CO (JP) | 1998-06-24 | — | — | CN | disclosed |
| CN-1116427-A | Novel polypeptide and anti-HIV agent prepared from the same | SEIKAGAKU KOGYO CO LTD (JP) | 1996-02-07 | — | — | CN | disclosed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | disclosed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | ACE 3845/4885REN 2024/4885KDM4E 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.